Anabolic steroid use: the physique goals behind the survey numbers
Anabolic steroid use extends well beyond athletes trying to win a contest. In its 2021 explanation of an American College of Sports Medicine consensus statement, sports physician Michele LaBotz identified the predominant group as male recreational athletes seeking greater muscle size. She also identified muscle dysmorphia as a major risk factor for misuse. Research on users and gym communities gives that distinction substance: competitive performance, strength, appearance and anxiety about muscularity overlap, but they are not interchangeable motives.
A 2020 study, Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids, collected 2,385 eligible responses from adult men who had used the drugs within the previous five years. Its anonymous survey was promoted through nine online forums and a physician's educational YouTube channel. About 82% selected improving appearance or gaining muscle as a motive, 50% selected strength, and roughly 9% selected performance in organized athletics. Respondents could select more than one response. These percentages describe overlapping aims within a recruited sample, not exclusive categories or a census of all users.
The survey also found that about 39% feared losing muscle or worsening their appearance if they stopped. That connects the original attraction of anabolic steroid use with a reason to continue. However, its recruitment method leaves out people who did not encounter the invitation or chose not to disclose their behavior. The results establish what these respondents reported; they cannot establish how frequently every motive occurs in every country or training community.
A separate 2016 study of 248 German-speaking men who trained with weights examined the desire for muscularity more broadly. Most participants wanted more muscle and a better appearance, but only 8.9% reported current or former use of illegal physique-enhancing substances such as anabolic steroids. Internalizing the muscular body ideals presented in media was the strongest positive statistical predictor of the drive for muscularity. Dissatisfaction with muscle size and aspects of body-related self-esteem also mattered. This was not a sample consisting entirely of drug users, which is precisely why its distinction between wanting muscle and taking drugs is useful.
That study measured attitudes and behavior at one point in time. It therefore could not establish which came first: internalized ideals, dissatisfaction or particular training practices. Its largely Western, German-speaking sample also limited generalization. The association supplies evidence about a social and psychological setting for anabolic steroid use, without making every dissatisfied lifter a future user or treating a muscular appearance as a clinical diagnosis.
Research in French-speaking Switzerland followed the setting at closer range. A 2018 Frontiers in Psychology study combined approximately 100 gym observations over a year and a half with 30 interviews, including 23 men and seven women. Interviewees ranged from ordinary gym participants to people whose lives centered on bodybuilding. The researchers described a gradual shift in identity and social relationships as some participants became committed bodybuilders. None of the bodybuilders interviewed had entered the gym already intending to use doping substances. That finding concerned their reported trajectories, rather than a universal route into drug use.
The interviews placed changes in diet, training and pharmacological practices within that progression. Recognition by experienced bodybuilders and movement from outsider to accepted participant helped change what seemed normal or acceptable. The investigators did not reduce those changes to a single pre-existing psychological disorder. For anabolic steroid use, their qualitative findings describe changing relationships and behavior. The small, deliberately selected group cannot supply population prevalence.
The attraction of added muscle also has a physiological basis. Peter Bond, Diederik Smit and Willem de Ronde's 2022 endocrinology review describes anabolic-androgenic steroids entering target cells and acting through androgen receptors. The same hormonal system explains why gaining size does not isolate a user from effects elsewhere. External androgens suppress signals involved in the testes' own testosterone production and sperm production; suppression can persist after use stops. The review also distinguishes the effects of different compounds and routes of administration. Self-directed combinations taken to manage unwanted effects are not equivalent to established evidence that a regimen is safe.
LaBotz's ACSM discussion highlights a practical obstacle around anabolic steroid use: users had often spent substantial time investigating the drugs, yet few regarded physicians or pharmacists as knowledgeable. That finding concerns perceived expertise, which is different from demonstrated safety. A detailed drug routine can coexist with body-image concerns, changing social pressures and endocrine effects that continue beyond the period of visible gains. The combined research supports addressing those concrete motives and medical consequences. A strategy focused only on the possibility of a sports ban misses the appearance-centered goals that dominate the ACSM description and the large user survey.
- American College of Sports Medicine, Michele LaBotz (2021): Anabolic-Androgenic Steroid Use in Sports, Health and Society — acsm.org
- Bonnecaze, O'Connor and Aloi (2020): survey of 2,385 men using anabolic-androgenic steroids — pmc.ncbi.nlm.nih.gov
- Schneider and colleagues, Frontiers in Psychology (2016): Biological, Psychological, and Sociocultural Factors Contributing to the Drive for Muscularity in Weight-Training Men — www.frontiersin.org
- Coquet, Roussel and Ohl, Frontiers in Psychology (2018): bodybuilding fieldwork and interviews — www.frontiersin.org
- Bond, Smit and de Ronde, Frontiers in Endocrinology (2022): Anabolic-androgenic steroids: How do they work and what are the risks? — pmc.ncbi.nlm.nih.gov